Evofem Biosciences Honors World Contraception Day

Rhea-AI Summary

Evofem Biosciences (OTCID: EVFM) commemorates World Contraception Day by highlighting its commitment to women's reproductive health innovation. The company's flagship products include PHEXXI®, the first hormone-free, on-demand contraceptive vaginal gel, and SOLOSEC®, a single-dose treatment for bacterial vaginosis and trichomoniasis.

CEO Saundra Pelletier emphasizes the importance of providing women with flexible contraceptive options, particularly for those who want alternatives to hormonal birth control. The company's "Say Vagina" awareness campaign has reached millions, focusing on destigmatizing women's health conversations and improving health education.

Positive

• First and only FDA-approved hormone-free, on-demand contraceptive gel in the market
• Successful global awareness campaign 'Say Vagina' reaching millions
• Diversified product portfolio with both PHEXXI and SOLOSEC

Negative

• None.

SAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- On World Contraception Day, Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCID: EVFM) honors the millions of people worldwide who rely on contraception not only to prevent pregnancy, but to take control of their health, their futures, and their freedom. Access to contraception remains uneven across countries and communities; the need for more education, innovation, and de-stigmatization has never been greater.

Evofem's mission has always centered on challenging the status quo in women's health — offering groundbreaking choices where few exist and leading conversations others avoid. With products like PHEXXI^® (lactic acid, citric acid, and potassium bitartrate), the first and only hormone-free, on-demand contraceptive vaginal gel, and SOLOSEC^® (secnidazole) 2g oral granules, a single-dose oral treatment for bacterial vaginosis and trichomoniasis, Evofem is working to ensure women have more tools to safeguard their reproductive and sexual health.

"World Contraception Day is about making sure every person has access to safe, effective, and affordable choices," said Saundra Pelletier, CEO of Evofem Biosciences. "Let's be honest – most women do not have sex every day. They deserve a contraceptive option that enables them to have sex on demand and PHEXXI makes this possible.  We are proud to offer this non-hormonal innovative solution to the women who have suffered side effects from synthetic hormones in birth control; cancer thrivers; breast feeding mothers; and women who simply do not want to 'over-medicate' themselves with hormonal contraception."      

In addition to commercializing science-backed, FDA-approved products, Evofem is committed to awareness and education campaigns that confront stigma directly. The Company's international "Say Vagina" initiative has reached millions by challenging censorship, dismantling shame surrounding female anatomy, and improving health education. Through this campaign, Evofem is turning awareness into action.

As the Company looks ahead, Evofem remains dedicated to breaking barriers, expanding global access, and ensuring that women's health continues to receive the investment and innovation it deserves. On World Contraception Day, Evofem reaffirms its vision: a world where reproductive health options are celebrated, supported, and accessible to all.

About Evofem Biosciences
Evofem is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products.

PHEXXI^® (lactic acid, citric acid, and potassium bitartrate), is the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Visit phexxi.com to learn more and for important safety information.

SOLOSEC^® (secnidazole) 2g oral granules is an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information.

PHEXXI^® and SOLOSEC^® are registered trademarks of Evofem Biosciences, Inc.

Connect With Us
Media
Media@evofem.com

Investors and Potential Partners
Amy Raskopf, Chief Business Development Officer
Evofem Biosciences, Inc.
araskopf@evofem.com
(917) 673-5775

Join the Dialogue

LinkedIn	@evofem + @saundrapelletier
TikTok	@phexxi + @saundrapelletier
Instagram	@evofem, @phexxi + @saundrapelletier
X	@evofem + @SaundraCEO
Facebook	@evofem + @phexxi

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-honors-world-contraception-day-302568188.html

SOURCE Evofem Biosciences, Inc.

FAQ

What products does Evofem Biosciences (EVFM) offer for women's health?

Evofem offers PHEXXI®, the first hormone-free, on-demand contraceptive vaginal gel, and SOLOSEC®, a single-dose oral treatment for bacterial vaginosis and trichomoniasis.

What makes PHEXXI different from other contraceptives?

PHEXXI is the first and only hormone-free, on-demand contraceptive vaginal gel, offering an alternative for women who cannot or prefer not to use hormonal birth control.

What is Evofem's 'Say Vagina' campaign about?

The 'Say Vagina' campaign aims to challenge censorship, dismantle shame around female anatomy, and improve health education, reaching millions of people globally.

Who can benefit from using PHEXXI contraceptive gel?

PHEXXI is suitable for women who have experienced side effects from hormonal birth control, cancer survivors, breastfeeding mothers, and those who prefer non-hormonal contraception.

What is Evofem's mission in women's healthcare?

Evofem's mission is to challenge the status quo in women's health by offering groundbreaking choices, leading difficult conversations, and ensuring reproductive health options are accessible to all.